BD picks up CE mark for next-gen stent graft

BD (NYSE:BDX) announced today that it received CE mark approval for its Liverty TIPS stent graft system.

Franklin Lakes, New Jersey-based BD designed the stent graft to expand treatment options for patients with cirrhosis and complications of portal hypertension. The next-generation, adjustable-diameter device marks the latest advancement for the company in treating complex liver disease.

Liverty TIPS supports individualized patient management, with a 6-10 mm adjustable inner diameter. It also offers the broadest range of covered TIPS stent lengths currently available.

Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation. The stent graft has carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system. BD designed it for placement accuracy, control and ease of use.

Sign up for Blog Updates